Trial Profile
Phase IIIb Immunogenicity, Safety and Reactogenicity Study of GSK Biologicals' Meningococcal Vaccine [GSK 134612] When Given as One Dose to Healthy Subjects Aged 56 Years or Older
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 Sep 2023
Price :
$35
*
At a glance
- Drugs Meningococcal vaccine groups A C Y W-135 conjugate (Primary) ; Meningococcal vaccine groups A C Y W-135 polysaccharide
- Indications Meningococcal group A infections; Meningococcal group C infections; Meningococcal group W-135 infections; Meningococcal group Y infections; Meningococcal infections
- Focus Registrational; Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 19 Aug 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 19 Aug 2011 Actual end date (Aug 2011) added as reported by ClinicalTrials.gov.
- 01 Jul 2011 Planned end date changed from 1 Jun 2011 to 1 Jul 2011 as reported by ClinicalTrials.gov.